New drug cocktail aims to stop bile duct cancer from coming back

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically or pathologically confirmed malignant cholangiocarcinoma. * Patients who have undergone curative surgical resection. * Age between 18 and 75 years. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Expected survival time \>3 months. * Adequate organ and bone marrow function, including:Absolute neutrophil count ≥1.5 × 10\^9/L,Platelet count ≥75 × 10\^9/L,Hemoglobin ≥90 g/L,Total bilirubin ≤1.5 × upper limit of normal (ULN),AST and ALT ≤2.5 × ULN,Albumin ≥3 g/dL,Serum creatinine ≤1.5 × ULN. * Ability to understand and willingness to sign written informed consent. * For patients of childbearing potential, willingness to use effective contraception during the study and for at least 1 month after the last dose; negative pregnancy test within 72 hours prior to enrollment. Exclusion Criteria: * Prior treatment with immune checkpoint inhibitors or other agents targeting T-cell co-stimulatory or co-inhibitory pathways (e.g., CTLA-4, CD137). * Use of any investigational drug within 4 weeks prior to enrollment. * Active autoimmune disease or history of autoimmune disease (e.g., interstitial lung disease, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, or hypothyroidism requiring hormone replacement). * Known immunodeficiency, including HIV infection, active hepatitis B (HBV DNA \>500 IU/mL), active hepatitis C (HCV RNA above detection limit), or co-infection of HBV and HCV. * Severe infection within 4 weeks prior to first dose or unexplained fever \>38.5°C during screening. * History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. * Uncontrolled psychiatric disorders. * Severe or uncontrolled comorbidities that may interfere with study participation (e.g., unstable angina, myocardial infarction within 6 months, symptomatic arrhythmia, congestive heart failure, uncontrolled diabetes, or uncontrolled infection). * History of other malignancies within the past 5 years, except for non-melanoma skin cancer or carcinoma in situ. * Known hypersensitivity to study drugs or monoclonal antibodies. * Inability or unwillingness to provide informed consent.